ERBB2 and breast carcinoma: Furthermore, using The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data sets, we show ECD mRNA overexpression correlates with short patient survival, specifically in ErbB2+ as well as triple-negative breast cancer (TNBC) patients, and serves as an independent prognostic marker.